The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Why is COVID‐19 so mild in children?
Open accessAbstract
There is an urgent need to understand why the course of the coronavirus that started in late 2019 (COVID-19) is affecting different groups of individuals with varying severity during the ongoing global pandemic. Greater knowledge of the disease, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), will help us to prioritise our limited health resources. Because the virus is new, and no vaccine is yet available, everyone is naïve and susceptible to being infected with SARS-CoV2. The virus will continue to spread until an effective vaccine exists or sufficient members of our global population have been infected to establish herd immunity. At the moment, the best way to minimise loss of life and severe cases requiring intensive care is to try and shelter vulnerable groups of individuals and slow down the spread of the virus. The Korean Center for Disease Control and Prevention has probably tested the most extensive and therefore the most representative population. It reported that, up to 20 March, 6.3% of all cases that tested positive for COVID-19 were children under 19 years of age. The data from Korea are frequently being updated.1 It is still unclear how many of the population who have been tested belonged to the same age group, so enrichment of COVID-19 within this young adult age group is uncertain. However, a general pattern has been reported from multiple countries and that is that children who test positive for COVID-19 experience a mild form of the disease. This means that children and younger adults who do not have underlying conditions, such as impaired lung function or immunosuppression, have a much lower risk of severe forms of COVID-19 than other age groups. The reasons for this mild COVID-19 disease in children remain elusive, and multiple hypotheses exist. This editorial discusses some of those theories. On a general note, the immune systems of children and adults are different, both with respect to their composition and functional responsiveness.2 In addition, there are differences in the immune systems of very young children, preschool children and teenagers. During the first weeks of life, the human newborn infant is exposed to a range of novel environmental exposures and undergoes dramatic changes.3 Another difference between newborn infants and older children is the presence of some maternal antibodies during the first months of life. These antibodies do not include novel viruses such as SARS-CoV2.4 One possible explanation for the milder COVID-19 disease presentation in children is that children have a qualitatively different response to the SARS-CoV2 virus to adults. Another possibility is that the presence of other simultaneous viruses in the mucosa of lungs and airways, which are common in young children, could limit the growth of SARS-CoV2 by direct virus-to-virus interactions and competition.5 This fits with emerging data from the current pandemic, which has indicated a link between the amount of viral copies and COVID-19 severity.6 This could also explain some of the tragic deaths of healthcare workers, who have probably been exposed to large amounts of the SARS-Cov2 virus. Another possible theory for the mild COVID-19 infections in children is related to differences in the expression of the angiotensin-converting enzyme (ACE) 2 receptor necessary for SARS-Cov2 binding and infection. This receptor is expressed in the airways, the lung and intestines, but not in the immune cells.7 Treatment with ACE inhibitors or angiotensin receptor blockers induces expression of ACE2. Both therapies are common in adults with hypertension and much less common in children. This has led some to believe that elevated ACE2 expression could explain the worse outcomes in adults infected with SARS-Cov2, but others have reported protective effects of ACE2 during lung infections.8 Severe COVID-19 disease is characterised by three phases. The viral and pulmonary phases are followed by the final hyperinflammatory phase, which can lead to severe acute respiratory distress syndrome (ARDS), impaired cardiac function and death. Children are not less prone to developing ARDS during respiratory tract infections than adults.9 In fact, during the H1N1 flu pandemic in 2009, being under the age of one year was a significant risk factor for developing a severe form of the infection and ARDS.10 The reasons for the mild presentation in most children with COVID-19 are not clear at the moment, but several plausible mechanisms exist within the fields of immunology, anatomy and virology. Further studies will be required to test these hypotheses, but it is clear that understanding the milder COVID-19 disease in children will provide important information about the disease. It will also suggest important protective mechanisms and suggest targets for future therapies. There is a final point that I would like to make, and that is that even though children tend to have mild forms of COVID-19, that do
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Evolution of the immune system in humans from infancy to old age
Simon, A. K., Hollander, G. A., & McMichael, A. (2015) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2014.3085 · Cited by 1,796
Viral dynamics in mild and severe cases of COVID-19
Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727
Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection
(2010) · New England Journal of Medicine · doi:10.1056/nejmra1000449 · Cited by 1,062
Stereotypic Immune System Development in Newborn Children
Olin, A., Henckel, E., Chen, Y., Lakshmikanth, T., Pou, C., Mikes, J., Gustafsson, A., Bernhardsson, A. K., Zhang, C., Bohlin, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.045 · Cited by 696
Self-citationA genome-wide transcriptomic analysis of protein-coding genes in human blood cells
Uhlen, M., Karlsson, M. J., Zhong, W., Tebani, A., Pou, C., Mikes, J., Lakshmikanth, T., Forsström, B., Edfors, F., Odeberg, J., et al. (2019) · Science · doi:10.1126/science.aax9198 · Cited by 594
Self-citationVirus–virus interactions impact the population dynamics of influenza and the common cold
Nickbakhsh, S., Mair, C., Matthews, L., Reeve, R., Johnson, P. C. D., Thorburn, F., von Wissmann, B., Reynolds, A., McMenamin, J., Gunson, R. N., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911083116 · Cited by 530
A Well Infant With Coronavirus Disease 2019 With High Viral Load
Kam, K.-Q., Yung, C. F., Cui, L., Tzer Pin Lin, R., Mak, T. M., Maiwald, M., Li, J., Chong, C. Y., Nadua, K., Tan, N. W. H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa201 · Cited by 373
The repertoire of maternal anti-viral antibodies in human newborns
Pou, C., Nkulikiyimfura, D., Henckel, E., Olin, A., Lakshmikanth, T., Mikeš, J., Wang, J., Chen, Y., Bernhardsson, A. K., Gustafsson, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0392-8 · Cited by 140
Self-citationViral Infection in the Development and Progression of Pediatric Acute Respiratory Distress Syndrome
Nye, S., Whitley, R. J., & Kong, M. Y. F. (2016) · Frontiers in Pediatrics · doi:10.3389/fped.2016.00128 · Cited by 52
Cited by
COVID-19 pathophysiology: A review
Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108427 · Cited by 2,206
The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19
Consiglio, C. R., Cotugno, N., Sardh, F., Pou, C., Amodio, D., Rodriguez, L., Tan, Z., Zicari, S., Ruggiero, A., Pascucci, G. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.016 · Cited by 919
Self-citationImmune response, inflammation, and the clinical spectrum of COVID-19
García, L. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01441 · Cited by 739
Immune determinants of COVID-19 disease presentation and severity
Brodin, P. (2021) · Nature Medicine · doi:10.1038/s41591-020-01202-8 · Cited by 663
Self-citationImpact of COVID -19 on children: special focus on the psychosocial aspect
Ghosh, R., Dubey, M. J., Chatterjee, S., & Dubey, S. (2020) · Minerva Pediatrica · doi:10.23736/s0026-4946.20.05887-9 · Cited by 601
Metadata
- Authors
- Brodin, P.
- Venue
- Acta Paediatrica
- Publisher
- Wiley
- Published
- 2020-04-15
- Volume
- 109
- Issue
- 6
- Pages
- 1082-1083
- ISSN
- 0365-1436 (ISSN-L)
- 0803-5253
- 1651-2227
- OpenAlex
- W3012886343
- Cited by
- 345
- References
- 10
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why is COVID‐19 so mild in children? https://app.cochat.ai/papers/10.1111/apa.15271
- The paper
- Brodin, P. (2020). Why is COVID‐19 so mild in children? Acta Paediatrica. https://doi.org/10.1111/apa.15271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.